

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L2	23	banchereau adj jacques	US-PGPUB; USPAT; DERWENT	OR	ON	2005/08/16 07:53
L3	4	palucka adj anna	US-PGPUB; USPAT; DERWENT	OR	ON	2005/08/16 07:53
L5	2	blanco adj patrick	US-PGPUB; USPAT; DERWENT	OR	ON	2005/08/16 07:53

=> d 'his

(FILE 'HOME' ENTERED AT 08:51:42 ON 16 AUG 2005)

FILE 'MEDLINE, CAPLUS, BIOSIS' ENTERED AT 08:52:03 ON 16 AUG 2005
E BANCHEREAU JACQUES /AU

L1 546 S E3
E PALUCKA ANNA /AU

L2 5 S E5

L3 1 S E4

E BLANCO PARTICK /AU

L4 41 S E8

L5 18 S L1 (L) L4

L6 12 DUP REM L5 (6 DUPLICATES REMOVED)

L6 ANSWER 1 OF 12 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI Dendritic cells: Controllers of the immune system and a new promise for
immunotherapy.
PY 2003
AU **Banchereau, Jacques; Paczesny, Sophie; Blanco, Patrick**
; Bennett, Lynda; Pascual, Virginia; Fay, Joseph; Palucka, A. Karolina
[Reprint Author]
SO Chiorazzi, Nicholas [Editor, Reprint Author]; Lahita, Robert G. [Editor];
Capra, J. Donald [Editor]; Ferrarini, Manlio [Editor]; Zabriskie, John B.
[Editor]. (2003) pp. 180-187. Immune mechanisms and disease. print.
Publisher: New York Academy of Sciences, 2 East 63rd Street, New York, NY,
10021, USA. Series: Annals of the New York Academy of Sciences.
Meeting Info.: Conference on Immune Mechanisms and Disease. St. George's,
Grenada, West Indies, Windward Islands. April 14-17, 2002. Henry Kunkel
Society; New York Academy of Sciences.
ISSN: 0077-8923 (ISSN print). ISBN: 1-57331-434-X (cloth), 1-57331-435-8
(paper).

AU **Banchereau, Jacques; Paczesny, Sophie; Blanco, Patrick**
; Bennett, Lynda; Pascual, Virginia; Fay, Joseph; Palucka, A. Karolina
[Reprint Author]

L6 ANSWER 2 OF 12 MEDLINE on STN DUPLICATE 1
TI Dendritic cells: controllers of the immune system and a new promise for
immunotherapy.

PY 2003

AU **Banchereau Jacques; Paczesny Sophie; Blanco Patrick;**
Bennett Lynda; Pascual Virginia; Fay Joseph; Palucka A Karolina
SO Annals of the New York Academy of Sciences, (2003 Apr) 987 180-7. Ref: 22
Journal code: 7506858. ISSN: 0077-8923.
AU **Banchereau Jacques; Paczesny Sophie; Blanco Patrick;**
Bennett Lynda; Pascual Virginia; Fay Joseph; Palucka A Karolina

L6 ANSWER 3 OF 12 MEDLINE on STN DUPLICATE 2
TI Blood dendritic cells and DC-poietins in systemic lupus erythematosus.
PY 2002

AU Gill Michelle A; **Blanco Patrick**; Arce Edsel; Pascual Virginia;
Banchereau Jacques; Palucka A Karolina
SO Human immunology, (2002 Dec) 63 (12) 1172-80.
Journal code: 8010936. ISSN: 0198-8859.
AU Gill Michelle A; **Blanco Patrick**; Arce Edsel; Pascual Virginia;
Banchereau Jacques; Palucka A Karolina

L6 ANSWER 4 OF 12 MEDLINE on STN DUPLICATE 3
TI The interplay of dendritic cell subsets in systemic lupus erythematosus.
PY 2002

AU Palucka A Karolina; **Banchereau Jacques; Blanco Patrick**
; Pascual Virginia
SO Immunology and cell biology, (2002 Oct) 80 (5) 484-8. Ref: 40
Journal code: 8706300. ISSN: 0818-9641.
AU Palucka A Karolina; **Banchereau Jacques; Blanco Patrick**
; Pascual Virginia

L6 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN
TI Introduction to dendritic cells
PY 2002

AU **Blanco, Patrick; Palucka, A. Karolina; Banchereau, Jacques**
SO Gene Therapy of Cancer (2nd Edition) (2002), 167-177. Editor(s): Lattime,
Edmund C.; Gerson, Stanton L. Publisher: Academic Press, San Diego, Calif.
CODEN: 69CXHL; ISBN: 0-12-437551-0
AU **Blanco, Patrick; Palucka, A. Karolina; Banchereau, Jacques**

L6 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 4
TI Induction of dendritic cell differentiation by IFN- α in systemic
lupus erythematosus
PY 2001
AU **Blanco, Patrick; Palucka, A. Karolina; Gill, Michelle; Pascual,**

Virginia; Banchereau, Jacques
SO, Science (Washington, DC, United States) (2001), 294(5546), 1540-1543
CODEN: SCIEAS; ISSN: 0036-8075
AU Blanco, Patrick; Palucka, A. Karolina; Gill, Michelle; Pascual, Virginia; Banchereau, Jacques

L6 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 5
TI Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells
PY 2000
AU Berard, Frederic; Blanco, Patrick; Davoust, Jean; Neidhart-Berard, Eve-Marie; Nouri-Shirazi, Mahyar; Taquet, Nicolas; Rimoldi, Donata; Cerottini, Jean Charles; Banchereau, Jacques; Palucka, A. Karolina
SO Journal of Experimental Medicine (2000), 192(11), 1535-1543
CODEN: JEMEAV; ISSN: 0022-1007
AU Berard, Frederic; Blanco, Patrick; Davoust, Jean; Neidhart-Berard, Eve-Marie; Nouri-Shirazi, Mahyar; Taquet, Nicolas; Rimoldi, Donata; Cerottini, Jean Charles; Banchereau, Jacques; Palucka, A. Karolina

L6 ANSWER 8 OF 12 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI Altered B cells and dendritic cells in SLE.
PY 2000
AU Pascual, Virginia [Reprint author]; Arce, Edsel; Gill, Michelle; Jackson, Deborah; Blanco, Patrick; Pulendran, Bali; Palucka, Karolina; Banchereau, Jacques
SO FASEB Journal, (April 20, 2000) Vol. 14, No. 6, pp. A1209. print.
Meeting Info.: Joint Annual Meeting of the American Association of Immunologists and the Clinical Immunology Society. Seattle, Washington, USA. May 12-16, 2000.
CODEN: FAJOEC. ISSN: 0892-6638.
AU Pascual, Virginia [Reprint author]; Arce, Edsel; Gill, Michelle; Jackson, Deborah; Blanco, Patrick; Pulendran, Bali; Palucka, Karolina; Banchereau, Jacques

L6 ANSWER 9 OF 12 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI Dendritic cells loaded with killed allogeneic melanoma cells induce melanoma specific immunity.
PY 2000
AU Blanco, Patrick [Reprint author]; Berard, Frederic [Reprint author]; Davoust, Jean [Reprint author]; Taquet, Nicolas [Reprint author]; Rolland, Alexandre [Reprint author]; Nouri-Shirazi, Mahyar [Reprint author]; Kraus, Elizabeth T. [Reprint author]; Rimoldi, Donata; Cerottini, Jean Charles; Banchereau, Jacques [Reprint author]; Palucka, Karolina A. [Reprint author]
SO FASEB Journal, (April 20, 2000) Vol. 14, No. 6, pp. A946. print.
Meeting Info.: Joint Annual Meeting of the American Association of Immunologists and the Clinical Immunology Society. Seattle, Washington, USA. May 12-16, 2000.
CODEN: FAJOEC. ISSN: 0892-6638.
AU Blanco, Patrick [Reprint author]; Berard, Frederic [Reprint author]; Davoust, Jean [Reprint author]; Taquet, Nicolas [Reprint author]; Rolland, Alexandre [Reprint author]; Nouri-Shirazi, Mahyar [Reprint author]; Kraus, Elizabeth T. [Reprint author]; Rimoldi, Donata; Cerottini, Jean Charles; Banchereau, Jacques [Reprint author]; Palucka, Karolina A. [Reprint author]

L6 ANSWER 10 OF 12 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI Dendritic cells capture tumor cell bodies and process/present their antigens to elicit tumorspecific immune responses.
PY 2000
AU Palucka, Karolina [Reprint author]; Nouri-Shirazi, Mahyar [Reprint author]; Blanco, Patrick [Reprint author]; Berard, Frederic [Reprint author]; Neidhart-Berard, Eve-Marie [Reprint author]; Burkeholder, Susan [Reprint author]; Kraus, Elizabeth [Reprint author]; Davoust, Jean [Reprint author]; Banchereau, Jacques [Reprint

author]
SO Journal of Investigative Dermatology, (Jan., 2000) Vol. 114, No. 1, pp. 236. print.
Meeting Info.: The Sixth International Workshop on Langerhans Cells. New York, New York, USA. October 08-10, 1999.
CODEN: JIDEAE. ISSN: 0022-202X.

AU Palucka, Karolina [Reprint author]; Nouri-Shirazi, Mahyar [Reprint author]; **Blanco, Patrick** [Reprint author]; Berard, Frederic [Reprint author]; Neldhart-Berard, Eve-Marie [Reprint author]; Burkeholder, Susan [Reprint author]; Kraus, Elizabeth [Reprint author]; Davoust, Jean [Reprint author]; **Banchereau, Jacques** [Reprint author]

L6 ANSWER 11 OF 12 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN

TI Dendritic cells capture breast cancer cells and present their antigens to elicit tumor-specific CD4+ and CD8+ T cells.

PY 2000

AU Neidhardt-Berard, Eve-Marie [Reprint author]; Berard, Frederic [Reprint author]; **Blanco, Patrick** [Reprint author]; Minna, John; Gazdar, Adi; **Banchereau, Jacques** [Reprint author]; Palucka, Karolina [Reprint author]

SO Blood, (November 16, 2000) Vol. 96, No. 11 Part 2, pp. 30b-31b. print.
Meeting Info.: 42nd Annual Meeting of the American Society of Hematology. San Francisco, California, USA. December 01-05, 2000. American Society of Hematology.
CODEN: BLOOAW. ISSN: 0006-4971.

AU Neidhardt-Berard, Eve-Marie [Reprint author]; Berard, Frederic [Reprint author]; **Blanco, Patrick** [Reprint author]; Minna, John; Gazdar, Adi; **Banchereau, Jacques** [Reprint author]; Palucka, Karolina [Reprint author]

L6 ANSWER 12 OF 12 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN

TI Dendritic cell subsets in pediatric Lupus patients.

PY 2000

AU Gill, Michelle A. [Reprint author]; **Blanco, Patrick**; **Banchereau, Jacques**; Pascual, Virginia; Pulendran, Bali; Palucka, Karolina

SO Pediatric Research, (April, 2000) Vol. 47, No. 4 Part 2, pp. 17A. print.
Meeting Info.: Joint Meeting of the Pediatric Academic Societies and the American Academy of Pediatrics. Boston, Massachusetts, USA. May 12-16, 2000. American Academy of Pediatrics; American Pediatric Society; Society for Pediatric Research.
CODEN: PEREBL. ISSN: 0031-3998.

AU Gill, Michelle A. [Reprint author]; **Blanco, Patrick**; **Banchereau, Jacques**; Pascual, Virginia; Pulendran, Bali; Palucka, Karolina

=> d his

(FILE 'HOME' ENTERED AT 08:51:42 ON 16 AUG 2005)

FILE 'MEDLINE, CAPLUS, BIOSIS' ENTERED AT 08:52:03 ON 16 AUG 2005

E BANCHEREAU JACQUES /AU

L1 546 S E3

E PALUCKA ANNA /AU

L2 5 S E5

L3 1 S E4

E BLANCO PARTICK /AU

L4 41 S E8

L5 18 S L1 (L) L4

L6 12 DUP REM L5 (6 DUPLICATES REMOVED)

L7 48026 S PSORIASIS

L8 38666 S AUTOIMMUNIT?

L9 123 S L7 (L) L8

L10 31779 S SLE

L11 15 S L9 (L) L10

L12 8 DUP REM L11 (7 DUPLICATES REMOVED)

L12 ANSWER 1 OF 8 MEDLINE on STN
TI Connective tissue disease in children.
PY 2005
AU Buka Robert L; Cunningham Bari B
SO Pediatric annals, (2005 Mar) 34 (3) 225-9, 233-8. Ref: 36
Journal code: 0356657. ISSN: 0090-4481.
AB As our understanding of connective tissue disease expands, so too does our therapeutic armamentarium. We have learned that **autoimmunity** triggers inflammation through unchecked, proliferative cell-mediated inflammation. By targeting this arm of the cytokine cascade, it may be possible to. . . further progression. Several biologic agents, such as etanercept, alefacept, infliximab, efaluzimab, and, recently, adalimumab, have come to market for adult **psoriasis** and are now undergoing trials for juvenile **SLE**, **psoriasis**, and **psoriatic arthritis**. Of note, etanercept has been used successfully in juvenile rheumatoid arthritis for more than 10 years. These. . .

L12 ANSWER 2 OF 8 MEDLINE on STN DUPLICATE 1
TI Recent findings on genes associated with inflammatory disease.
PY 2005
AU Yamada Ryo; Yamamoto Kazuhiko
SO Mutation research, (2005 Jun 3) 573 (1-2) 136-51. Ref: 75
Journal code: 0400763. ISSN: 0027-5107.
AB . . . of medical conditions. In this chapter, autoimmune diseases and allergic disorders will be our focus. The autoimmune diseases include organ-specific **autoimmunities**, such as type I diabetes mellitus and autoimmune thyroiditis (AITD), and organ non-specific disorders such as systemic lupus erythematosus (**SLE**). All of them seem to share aspects of aberrant immunologic tolerance toward self-antigens. Asthma and atopic diathesis are among the allergies. Crohn disease and **SLE** are relatively rare with a prevalence of 10-50 per 100,000, and rheumatoid arthritis (RA), **psoriasis**, AITD and asthma are commoner with a prevalence of 500 per 100,000 or much higher. The difference among ethnic groups is not prominent for rheumatoid arthritis, **psoriasis**, AITD or asthma, but Crohn disease and **SLE** affect some ethnic populations more than others. Although all of these disorders have some environmental component, asthma and atopy seem. . .

L12 ANSWER 3 OF 8 MEDLINE on STN DUPLICATE 2
TI Different familial association patterns of autoimmune diseases between juvenile-onset systemic lupus erythematosus and juvenile rheumatoid arthritis.
PY 2004
AU Huang Chun-Mei; Yang Yao-Hsu; Chiang Bor-Luen
SO Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, (2004 Apr) 37 (2) 88-94.
Journal code: 100956211. ISSN: 1684-1182.
AB . . . this study was to determine if the prevalence of autoimmune disorders in the relatives of patients with systemic lupus erythematosus (**SLE**) is greater than that of relatives of patients with juvenile rheumatoid arthritis (JRA). Interviews were used to obtain histories of the following autoimmune disorders among living or deceased first-, second-, and third-degree relatives of 91 **SLE** and 110 JRA families: ankylosing spondylitis, **SLE**, rheumatoid arthritis (RA), JRA, multiple sclerosis, juvenile dermatomyositis, Sjogren's syndrome, myasthenia gravis, **psoriasis**, and thyroid diseases. There were statistically significant differences between the **SLE** and JRA probands in mean age and gender ratio (19.1 +/- 4.8 vs 14.0 +/- 5.5 years; M (male)/F (female): 17/74 vs 62/48, p<0.005). The prevalence rate of autoimmune diseases in relatives of **SLE** families (20.9%) was greater than in JRA families (11.8%), but not statistically significantly so. The mean age (18.0 +/- 5.3. . . 5/8) of the patients with affected relatives between these 2 groups all had statistically significant differences. A higher prevalence of **SLE** in relatives was found in **SLE** families than in JRA cases. Furthermore, this study revealed a higher incidence of autoimmune disorders among second- and third-degree relatives of **SLE** or JRA

probands versus first-degree ones, especially sisters (including 1 pair of twins) and the maternal aunt in **SLE** families. These data demonstrate that the prevalence of autoimmune disorders in the relatives of patients with **SLE** is greater than those of relatives of patients with JRA. This suggests that clinically different autoimmune phenotypes may share common susceptibility genes, which may act as risk factors for autoimmunity.

L12 ANSWER 4 OF 8 MEDLINE on STN DUPLICATE 3
TI IDEC-131. IDEC/Eisai.
PY 2002
AU Dumont Francis J
SO Current opinion in investigational drugs (London, England : 2000), (2002 May) 3 (5) 725-34. Ref: 60
Journal code: 100965718. ISSN: 1472-4472.
AB . . . IDEC licensed from Dartmouth Medical School where researchers demonstrated the biological effects of the anti-CD154 antibody in animal models of **autoimmunity**. In January 2001, phase II trials in **psoriasis** and idiopathic thrombocytopenic purpura (ITP) were initiated. By January 2002, a phase II trial in Crohn's disease was also ongoing. A pilot, multicenter, multiple-dose phase I trial in moderate-to-severe **psoriasis** was initiated in January 2001. This trial was ongoing in January 2002. IDEC, in collaboration with Dartmouth Medical School had. . . a phase I trial in multiple sclerosis by March 1999. IDEC-131 was also previously being developed for systemic lupus erythematosus (**SLE**), although no further development for this indication has been reported since the disclosure of disappointing phase II results in April. . .

L12 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN
TI Novel approaches to therapy for systemic lupus erythematosus
PY 2000
AU Zandman-Goddard, Gisele; Shoenfeld, Yehuda
SO European Journal of Internal Medicine (2000), 11(3), 130-134
CODEN: EJIMEJ; ISSN: 0953-6205
AB A review with 29 refs. Current therapies for systemic lupus erythematosus (**SLE**) are targeted at immunosuppression and at reducing inflammation. The current therapies are broad-spectrum and include steroids and cytotoxic agents that. . . by toxicity and side effects of the medications. Methotrexate can be utilized to reduce steroid requirements in mild to moderate **SLE**. Manipulation of the hormonal axis includes DHEA and bromocriptine. Mycophenolate mofetil is an immunosuppressive agent that is being investigated for **SLE** renal disease. Autologous stem cell transplantation or high-dose cyclophosphamide may be an option for severe refractory **SLE**. The aim of the future is to target therapies by altering specific known mechanisms of inflammation and **autoimmunity**. Although the inciting antigen is still unknown in **SLE**, it may be possible to alter the regulation of the immune response by targeted mol. therapy. Methods to do so. . . induction of tolerance by administration of blocking peptides. IVIg is an immunomodulator that has been successful in the treatment of **SLE**. Targeted mol. therapy is undergoing phase I trials with monoclonal anti-CD40L, a signaling inhibitor. Anti-CTLA4Ig, another signaling blocker, is presently being investigated for **psoriasis**, but may be a potential therapy for **SLE**. Finally, therapies may include the administration of peptides to induce tolerance.

L12 ANSWER 6 OF 8 MEDLINE on STN DUPLICATE 4
TI Familial aggregation of lupus and autoimmunity in an unusual multiplex pedigree.
PY 1999
AU Sestak A L; Shaver T S; Moser K L; Neas B R; Harley J B
SO Journal of rheumatology, (1999 Jul) 26 (7) 1495-9.
Journal code: 7501984. ISSN: 0315-162X.
AB OBJECTIVE: To evaluate an unusual pedigree with 8 members diagnosed with systemic lupus erythematosus (**SLE**) METHODS: Pedigree members were evaluated through questionnaires, interviews, and medical records.

. Sixty members contributed serum samples for autoantibody analysis.
RESULTS: . . . nephritis (4/8). A total of 15 of 51 (29%) blood relatives had autoantibodies; 9 had autoimmune disease, including 7 with SLE, one with psoriasis, and one with Sjogren's syndrome. Five of 11 (45%) nonconsanguineous spouses also had autoantibodies; one spouse had SLE, and 2 others had thyroid disease. Among 68 spouses of patients with SLE in other pedigrees, only 9 (13%) had autoantibodies, and none were symptomatic (p = 0.02). CONCLUSION: The high rate of autoimmunity among both blood relatives and nonconsanguineous mates in this unusual pedigree suggests a complex interaction of genetic and environmental factors. . .

L12 ANSWER 7 OF 8 MEDLINE on STN DUPLICATE 5
TI HLA typing in a large family with multiple cases of different autoimmune diseases.
PY 1997
AU Sels F; Westhovens R; Emonds M P; Vandermeulen E; Dequeker J
SO Journal of rheumatology, (1997 May) 24 (5) 856-9.
Journal code: 7501984. ISSN: 0315-162X.
AB . . . OBJECTIVE: Because of the concurrence, in members of one family, of different autoimmune disorders [rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), psoriasis (PS), and inflammatory bowel disease (IBD)], we investigated the genotypes of each member and compared the results with current knowledge. . . ad 4 of 5 showed the maternal A2B51DR4 haplotype. Two of 3 siblings with the genotype HLA-A2/3, B8/35, DR2/3 had SLE. Patients with IBD and psoriasis shared the haplotype HLA-A3, B35 CW4 DR2. CONCLUSION: The results show that the important role of patients, sex and confirm the association between HLA haplotype and RA or SLE. They support the hypothesis that autoimmunity is a mendelian dominant trait, and that secondary genes, including these of the major histocompatibility complex, confer phenotypic specificity.

L12 ANSWER 8 OF 8 MEDLINE on STN DUPLICATE 6
TI T cell antigen receptors in autoimmunity.
PY 1988
AU Posnett D N; Gottlieb A; Bussel J B; Friedman S M; Chiorazzi N; Li Y; Szabo P; Farid N R; Robinson M A
SO Journal of immunology (Baltimore, Md. : 1950), (1988 Sep 15) 141 (6) 1963-9.
Journal code: 2985117R. ISSN: 0022-1767.
AB . . . autoimmune diseases, TCR were analyzed in different autoimmune diseases and control groups including rheumatoid arthritis, Graves disease, idiopathic thrombocytopenic purpura, psoriasis, SLE, insulin-dependent diabetes mellitus, and in nonautoimmune control diseases and normals. Purified T cells were stained by indirect immunofluorescence with three. . . available mAb, could not be associated with any of the diseases studied. Examination of T cells at the site of autoimmunity, such as T cells from rheumatoid arthritis synovial fluid, revealed normal percentages of cells staining with these mAb. Immunoperoxidase staining. . .

=> d his

(FILE 'HOME' ENTERED AT 09:30:18 ON 16 AUG 2005)

FILE 'CAPLUS, MEDLINE, BIOSIS' ENTERED AT 09:30:33 ON 16 AUG 2005

L1 97046 S AUTOIMMUNE (1W) DISEASE
L2 201 S INTERFERON (1W) ANTAGONIST
L3 772 S INTERFERON ANTIBODY
L4 7 S L1 (L) L3
L5 4 S L1 (L) L2
L6 0 S L4 (L) L5
L7 7 DUP REM L4 (0 DUPLICATES REMOVED)
L8 4 DUP REM L5 (0 DUPLICATES REMOVED)
L9 10 S L4 OR L5
L10 7 S L9 AND TREATMENT
L11 53593 S INTERFERON WITH ALPHA
L12 7865 S L11 AND ANTIBODY
L13 152 S L12 AND AUTOIMMUNITY
L14 103 S L13 AND TREATMENT
L15 0 S L14 AND INTERFERON WITH ANTAGONIST
L16 0 S L14 AND INTERFERON (W) ANTAGONIST
L17 0 S L14 AND ANTAGOIST
L18 64 DUP REM L14 (39 DUPLICATES REMOVED)
L19 0 S L18 AND INTERFREON (1W) (ALPHA OR TYPEI)
L20 0 S L18 AND INTERFORON (1W) ALPHA
L21 53593 S L11 AND INTERFERON (1W) ALPHA
L22 55 S L18 AND PY<2003
L23 0 S L22 AND INTERFERON WITH ALPHA SAME ANTIBODY
L24 316 S INTERFERON WITH ALPHA WITH ANTIBODY
L25 30 S L24 AND AUTOIMMUNE WITH DISEASE
L26 14 S L25 AND TREATMENT
L27 14 DUP REM L26 (0 DUPLICATES REMOVED)

TI Viral interferon antagonists and uses therefor

PY 2003

2004

2004

SO U.S. Pat. Appl. Publ., 28 pp.

CODEN: USXXCO

IN Palese, Peter; Garcia-sastre, Adolfo

TI Viral interferon antagonists and uses therefor

AB The present invention relates to compns. comprising one or more viral interferon antagonists and methods of utilizing said compns. to modulate the cellular interferon immune response. In particular, the present invention relates to pharmaceutical compns. comprising one or more viral interferon antagonists and methods of utilizing said compns. to prevent, treat or ameliorate an immune disorder characterized by aberrant interferon expression and/or. or ameliorating the symptoms of an inflammatory disorder comprising administering to a subject in need thereof one or more viral interferon antagonist. The present invention also relates to compns. comprising fusion proteins comprising one or more viral interferon antagonists and a heterologous polypeptide, and methods of using said compns. to modulate the cellular interferon immune response. The present invention further relates to articles of manufacture comprising one or more viral interferon antagonists or fusion proteins.

ST viral interferon antagonist fusion protein

antiinflammatory

IT Inflammation

(Crohn's disease; viral interferon antagonists and uses therefor)

IT Intestine, disease

(Crohn's; viral interferon antagonists and uses therefor)

IT Influenza A virus

(NS1; viral interferon antagonists and uses therefor)

IT Respiratory syncytial virus

(NS2; viral interferon antagonists and uses therefor)

IT Ebola virus

(VP35; viral interferon antagonists and uses therefor)

IT Interferons

RL: BSU (Biological study, unclassified); BIOL (Biological study) (antagonists; viral interferon antagonists and uses therefor)

IT Autoimmune disease

Inflammation

Thyroid gland, disease

(autoimmune thyroiditis; viral interferon antagonists and uses therefor)

IT Dermatitis

(contact; viral interferon antagonists and uses therefor)

IT Transplant and Transplantation

(graft-vs.-host reaction; viral interferon antagonists and uses therefor)

IT T cell (lymphocyte)

(helper cell/inducer, TH1; viral interferon antagonists and uses therefor)

IT Anti-inflammatory agents

Antiarthritics

Arthritis

Diabetes mellitus

Drug delivery systems

Graves' disease

Human

Immunosuppressants
Lyme disease
Multiple sclerosis
 Psoriasis
Sarcoidosis
Transplant rejection
 (viral interferon antagonists and uses therefor)

L5 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
TI Antagonist of Th1 immune response inducing cytokine for the treatment of
autoimmune diseases
PY 2001
2001
2002
2003
2003
SO PCT Int. Appl., 23 pp.
CODEN: PIXXD2
IN Tovey, Michael Gerard
TI Antagonist of Th1 immune response inducing cytokine for the treatment of
autoimmune diseases
AB . . . of T helper 1 cell responses, preferably for example a Type
1-interferon antibody, is disclosed for inhibition of prevention of
autoimmune diseases.
ST autoimmune disease therapy Th1 cytokine antagonist; interferon
antibody autoimmune disease therapy
IT Immunoglobulins
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
 (G; antagonists of Th1 cell-inducing cytokine for treatment of
 autoimmune diseases)
IT Autoimmune disease
Multiple sclerosis
 Psoriasis
 Rheumatoid arthritis
 (antagonists of Th1 cell-inducing cytokine for treatment of
 autoimmune diseases)
IT Cytokines
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
 (antagonists of Th1 cell-inducing cytokine for treatment of
 autoimmune diseases)
IT Antibodies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
 (antagonists of Th1 cell-inducing cytokine for treatment of
 autoimmune diseases)
IT T cell (lymphocyte)
 (helper cell/inducer, TH1; antagonists of Th1 cell-inducing cytokine
 for treatment of autoimmune diseases)
IT Diabetes mellitus
 (insulin-dependent; antagonists of Th1 cell-inducing cytokine for
 treatment of autoimmune diseases)
IT Antibodies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
 (monoclonal; antagonists of Th1 cell-inducing cytokine for treatment of
 autoimmune diseases)
IT Drug delivery systems
 (nasal; antagonists of Th1 cell-inducing cytokine for treatment of
 autoimmune diseases)
IT Drug delivery systems
 (oral; antagonists of Th1 cell-inducing cytokine for treatment of
 autoimmune diseases)
IT Cytokine receptors
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(soluble; antagonists of Th1 cell-inducing cytokine for treatment of autoimmune diseases)

IT Lupus erythematosus
(systemic; antagonists of Th1 cell-inducing cytokine for treatment of autoimmune diseases)

IT Interferon receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(α/β - interferon; antagonists of Th1 cell-inducing cytokine for treatment of autoimmune diseases)

IT Interferons
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(α/β ; antagonists of Th1 cell-inducing cytokine for treatment of autoimmune diseases)

IT Interferons
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(α ; antagonists of Th1 cell-inducing cytokine for treatment of autoimmune diseases)

L5 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN

TI Methods and compositions for modulating responsiveness to corticosteroids
PY 1998
2000
2000
1998
1998
2001
2000
2000
2000
2002
2002
1999

SO PCT Int. Appl., 112 pp.
CODEN: PIXXD2

IN Sekut, Les; Carter, Adam; Chayur, Tariq; Banerjee, Subhashis; Tracey, Daniel E.

IT Thyroid gland, disease
(autoimmune thyroiditis; methods and compns. for modulating responsiveness to corticosteroids in the treatment of a variety of inflammatory and immunol. diseases and disorders)

IT Eye, disease
Eye, disease
(autoimmune uveitis; methods and compns. for modulating responsiveness to corticosteroids by co-administration of another agent)

IT Arthritis
Encephalomyelitis
Meningitis
(autoimmune; methods and compns. for modulating responsiveness to corticosteroids by co-administration of another agent)

IT Antiasthmatics
Antirheumatic agents
Autoimmune disease
Dermatitis
Drug allergy
Eczema
Multiple sclerosis
Psoriasis
Sjogren's syndrome
Transplant rejection
(methods and compns. for modulating responsiveness to corticosteroids in the treatment of a variety of inflammatory and immunol. diseases and disorders)

IT Interferons

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(γ, antagonists; methods and compns. for modulating responsiveness to corticosteroids by co-administration of another agent)

=> d his ful.

(FILE 'HOME' ENTERED AT 17:01:07 ON 05 AUG 2005)

FILE 'MEDLINE, CAPLUS, BIOSIS' ENTERED AT 17:01:33 ON 05 AUG 2005

L1 201 SEA ABB=ON PLU=ON INTERFERON (1W) ANTAGONIST
L2 3 SEA ABB=ON PLU=ON L1 AND PSORIASIS
L3 11 SEA ABB=ON PLU=ON L1 AND AUTOIMMUNE?
L4 11 DUP REM L3 (0 DUPLICATES REMOVED)
L5 3 SEA ABB=ON PLU=ON L4 AND PSORIASIS

L17 ANSWER 1 OF 9 MEDLINE on STN
TI Connective tissue disease in children.
AU Buka Robert L; Cunningham Bari B
SO Pediatric annals, (2005 Mar) 34 (3) 225-9, 233-8. Ref: 36
Journal code: 0356657. ISSN: 0090-4481.

L17 ANSWER 2 OF 9 MEDLINE on STN DUPLICATE 1
TI Recent findings on genes associated with inflammatory disease.
AU Yamada Ryo; Yamamoto Kazuhiko
SO Mutation research, (2005 Jun 3) 573 (1-2) 136-51. Ref: 75
Journal code: 0400763. ISSN: 0027-5107.

L17 ANSWER 3 OF 9 MEDLINE on STN DUPLICATE 2
TI Different familial association patterns of autoimmune diseases between juvenile-onset systemic lupus erythematosus and juvenile rheumatoid arthritis.
AU Huang Chun-Mei; Yang Yao-Hsu; Chiang Bor-Luen
SO Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, (2004 Apr) 37 (2) 88-94.
Journal code: 100956211. ISSN: 1684-1182.

L17 ANSWER 4 OF 9 MEDLINE on STN DUPLICATE 3
TI IDEC-131. IDEC/Eisai.
AU Dumont Francis J
SO Current opinion in investigational drugs (London, England : 2000), (2002 May) 3 (5) 725-34. Ref: 60
Journal code: 100965718. ISSN: 1472-4472.

L17 ANSWER 5 OF 9 MEDLINE on STN
TI Antinuclear autoantibodies in flaky skin (fsn) mutant mice.
AU Withington Susan; Maltby-Askari Ellen; Welner Robert; Parker Russ; Pelsue Stephen C
SO Autoimmunity, (2002 May) 35 (3) 175-81.
Journal code: 8900070. ISSN: 0891-6934.

L17 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN
TI Novel approaches to therapy for systemic lupus erythematosus
AU Zandman-Goddard, Gisele; Shoenfeld, Yehuda
SO European Journal of Internal Medicine (2000), 11(3), 130-134
CODEN: EJIMEJ; ISSN: 0953-6205

L17 ANSWER 7 OF 9 MEDLINE on STN DUPLICATE 4
TI Familial aggregation of lupus and autoimmunity in an unusual multiplex pedigree.
AU Sestak A L; Shaver T S; Moser K L; Neas B R; Harley J B
SO Journal of rheumatology, (1999 Jul) 26 (7) 1495-9.
Journal code: 7501984. ISSN: 0315-162X.

L17 ANSWER 8 OF 9 MEDLINE on STN DUPLICATE 5
TI HLA typing in a large family with multiple cases of different autoimmune diseases.
AU Sels F; Westhovens R; Emonds M P; Vandermeulen E; Dequeker J
SO Journal of rheumatology, (1997 May) 24 (5) 856-9.
Journal code: 7501984. ISSN: 0315-162X.

L17 ANSWER 9 OF 9 MEDLINE on STN DUPLICATE 6
TI T cell antigen receptors in autoimmunity.
AU Posnett D N; Gottlieb A; Bussel J B; Friedman S M; Chiorazzi N; Li Y; Szabo P; Farid N R; Robinson M A
SO Journal of immunology (Baltimore, Md. : 1950), (1988 Sep 15) 141 (6) 1963-9.
Journal code: 2985117R. ISSN: 0022-1767.

=> d his

(FILE 'HOME' ENTERED AT 08:51:42 ON 16 AUG 2005)

FILE 'MEDLINE, CAPLUS, BIOSIS' ENTERED AT 08:52:03 ON 16 AUG 2005

E BANCHEREAU JACQUES /AU

L1 546 S E3

E PALUCKA ANNA /AU

L2 5 S E5

L3 1 S E4

E BLANCO PARTICK /AU

L4 41 S E8

L5 18 S L1 (L) L4

L6 12 DUP REM L5 (6 DUPLICATES REMOVED)

L7 48026 S PSORIASIS

L8 38666 S AUTOIMMUNIT?

L9 123 S L7 (L) L8

L10 31779 S SLE

L11 15 S L9 (L) L10

L12 8 DUP REM L11 (7 DUPLICATES REMOVED)

L13 49 S L9 AND TREATMENT

L14 38 DUP REM L13 (11 DUPLICATES REMOVED)

L15 992 S L10 (L) L8

L16 16 S L15 AND L7

L17 9 DUP REM L16 (7 DUPLICATES REMOVED)